NUBAD LLC
Greenville, SC · Biotech · Private
In vitro biophysical screening assay for identifying ligands that bind to a novel RNA structure in SARS-CoV-2 virus
nubadllc.com →- Grants
- $26M
- 50 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 3 granted · 0 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of Aminoglycoside-Nucleic Acid Conjugates for Inactivation of an Antibiotic Resistance-Conferring Aminoglycoside Sensing Riboswitch | $252,413 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Aminoglycoside-Nucleic Acid Conjugates for Inactivation of an Antibiotic Resistance-Conferring Aminoglycoside Sensing Riboswitch | $464,380 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Peptide Antibiotic Nucleic Acids | $299,600 | |
| Federal grant | Department of Health and Human Services · Phase II · A Rapid Assay for RNA Targeted Drugs | $663,747 | |
| Federal grant | Department of Health and Human Services · Phase II · A Rapid assay for RNA targeted drugs: Instrumentation Supplement | $81,648 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Aminoglycoside-Nucleic Acid Conjugates for Inactivation of an Antibiotic Resistance-Conferring Aminoglycoside Sensing Riboswitch | $211,967 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Screening the Ribosome for New Target Sites | $650,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Screening the Ribosome for New Target Sites | $325,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Aminoglycosides with reduced ototoxicity | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Aminoglycosides with reduced ototoxicity | $600,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Screening the Ribosome for New Target Sites | $325,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Aminoglycosides with reduced ototoxicity | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Nucleobase aminosugars with reduced ototoxicity | $305,919 | |
| Federal grant | Department of Health and Human Services · Phase I · Nucleobase aminosugars with reduced ototoxicity | $670,352 | |
| Federal grant | Department of Health and Human Services · Phase I · Nucleobase aminosugars with reduced ototoxicity | $364,433 | |
| Federal grant | Department of Health and Human Services · Phase I · Aminoglycosides with reduced ototoxicity via miRNA targeting | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Aminoglycosides with reduced ototoxicity via miRNA targeting | $754,902 | |
| Federal grant | Department of Health and Human Services · Phase I · Aminoglycosides with reduced ototoxicity via miRNA targeting | $12,288 | |
| Federal grant | Department of Health and Human Services · Phase I · Aminoglycosides with reduced ototoxicity via miRNA targeting | $44,940 | |
| Federal grant | Department of Health and Human Services · Phase I · Aminoglycosides with reduced ototoxicity via miRNA targeting | $397,674 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Delivery of chemically modified PNA oligomers | $803,782 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Delivery of chemically modified PNA oligomers | $299,999 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · A biophysical assay for RNA based resistance | $428,690 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · A biophysical assay for RNA based resistance | $288,889 | |
| Federal grant | Department of Health and Human Services · Phase I · Supplement Request LIDIA.AZANKIA | $13,475 | |
| Federal grant | Department of Health and Human Services · Phase I · Supplement Request Alain Letou | $16,800 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of peptide nucleic acid antibiotics | $999,985 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of peptide nucleic acid antibiotics | $1,999,542 | |
| Federal grant | Department of Health and Human Services · Phase I · Delivery of chemically modified PNA oligomers | $473,508 | |
| Federal grant | Department of Health and Human Services · Phase II · Aminoglycosides with reduced ototoxicity | $1,999,693 | |
| Federal grant | Department of Health and Human Services · Phase II · Aminoglycosides with reduced ototoxicity | $999,986 | |
| Federal grant | Department of Health and Human Services · Phase I · A biophysical assay for RNA based resistance | $139,801 | |
| Federal grant | Department of Health and Human Services · Phase I · A biophysical assay targeting an essential bacterial gene | $294,506 | |
| Federal grant | Department of Health and Human Services · Phase I · A biophysical assay targeting an essential bacterial gene | $488,495 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · A biophysical assay targeting Gyrase RNA | $521,003 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · A biophysical assay targeting Gyrase RNA | $294,506 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · A biophysical assay targeting SARS CoV-2 RNA | $299,900 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · A biophysical assay targeting SARS CoV-2 RNA | $598,589 | |
| Federal grant | Department of Health and Human Services · Phase I · A biophysical assay targeting an essential bacterial gene | $193,989 | |
| Federal grant | Department of Health and Human Services · Phase II · Ototoxicity of modified aminoglycosides | $989,230 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of peptide nucleic acid antibiotics | $999,557 | |
| Federal grant | Department of Health and Human Services · Phase II · Aminoglycosides with reduced ototoxicity | $999,707 | |
| Federal grant | Department of Health and Human Services · Phase I · A biophysical assay targeting Gyrase RNA | $226,497 | |
| Federal grant | Department of Health and Human Services · Phase I · A biophysical assay targeting SARS CoV-2 RNA | $298,689 | |
| Federal grant | Department of Health and Human Services · Phase II · Ototoxicity of modified aminoglycosides | $999,976 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of peptide nucleic acid antibiotics | $33,272 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of peptide nucleic acid antibiotics | $998,585 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of peptide nucleic acid antibiotics-supplement 1 | $133,089 | |
| Federal grant | Department of Health and Human Services · Phase II · Aminoglycosides with reduced ototoxicity | $999,707 | |
| Federal grant | Department of Health and Human Services · Phase II · Ototoxicity of modified aminoglycosides | $999,975 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3281 | UNITED BIOTHERAPEUTICS LLC | — | — |
| 3282 | TARGETSITE THERAPEUTICS CORPORATION | — | — |
| 3283 | Seranova Bio, Inc. | — | $15M |
| 3284 | NUBAD LLC | — | — |
| 3285 | NANOMATRONIX LLC | — | — |
| 3286 | PRECISION BIOTOOLS INC | — | — |
| 3287 | Athletic DNA, Inc. | — | $4.2M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.